Arvanitis CD et al. |
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. |
2018 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:30150398
|
Mohamed HE et al. |
Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. |
2018 |
J Pharm Biomed Anal |
pmid:29258046
|
Doroshow DB and LoRusso PM |
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. |
2018 |
Future Oncol |
pmid:29214842
|
Hurvitz SA et al. |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. |
2018 |
Lancet Oncol. |
pmid:29175149
|
Ricci F and Le Tourneau C |
Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence? |
2018 |
Chin Clin Oncol |
pmid:29156892
|
Moore KN et al. |
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29098867
|
Zuradelli M et al. |
Never too old to fight breast cancer: A case report. |
2018 |
Medicine (Baltimore) |
pmid:29489698
|
Madden R et al. |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. |
2018 |
Int J Clin Pharmacol Ther |
pmid:29231164
|
Vilela MD et al. |
Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment. |
2018 |
World Neurosurg |
pmid:29274446
|
Nittoli T et al. |
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. |
2018 |
Bioorg. Med. Chem. |
pmid:29605304
|